Tenax Therapeutics (NASDAQ:TENX) Releases Earnings Results, Beats Expectations By $0.88 EPS

Tenax Therapeutics (NASDAQ:TENX) announced its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.26) by $0.88, FiscalAI reports.

Here are the key takeaways from Tenax Therapeutics’ conference call:

• Tenax announced it hit its enrollment target of 230 PH‑HFpEF patients for LEVEL ahead of plan, expects to complete randomization in March, and now narrows topline timing to Q3 for the 12‑week readout.
• Management reports strong trial engagement — consumption/compliance on the TID oral regimen is very high and >90% of patients enter the open‑label extension — suggesting favorable tolerability and retention.
• A blinded sample‑size reassessment showed the six‑minute‑walk standard deviation is lower than the conservative assumption, materially increasing the study’s power to >90% without changing the planned statistical approach.
• Executives emphasized a clear mechanistic proof‑of‑concept for oral levosimendan — splanchnic dilation/volume redistribution — supported by HELP phase II hemodynamics and comparable effects seen with invasive splanchnic block/vena cava device data, with accompanying functional improvement signals.
• LEVEL‑2 will be a larger, global 26‑week study (roughly double the subjects) across multiple regions; management expects multi‑year enrollment and plans to continue building safety data before pursuing regulatory discussions or submissions.

Tenax Therapeutics Stock Up 0.8%

Shares of NASDAQ:TENX opened at $14.62 on Thursday. The firm has a market cap of $91.23 million, a P/E ratio of -10.99 and a beta of 1.41. Tenax Therapeutics has a 12-month low of $4.63 and a 12-month high of $18.38. The business has a fifty day simple moving average of $13.26 and a 200 day simple moving average of $9.87.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on TENX shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a research note on Monday, December 22nd. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Tuesday. Finally, Guggenheim restated a “buy” rating and set a $25.00 target price (up from $14.00) on shares of Tenax Therapeutics in a research note on Wednesday, December 17th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $22.50.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC bought a new stake in shares of Tenax Therapeutics in the 3rd quarter valued at $92,000. Letko Brosseau & Associates Inc. bought a new position in Tenax Therapeutics during the fourth quarter worth $130,000. Corient Private Wealth LLC bought a new stake in shares of Tenax Therapeutics during the 4th quarter valued at about $151,000. Quadrature Capital Ltd acquired a new stake in Tenax Therapeutics during the fourth quarter worth approximately $252,000. Finally, Goldman Sachs Group Inc. acquired a new stake in Tenax Therapeutics during the fourth quarter worth approximately $273,000. Institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.